Search
Oral Presentation
Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab
Z. Piotrowska, D. Nguyen, V.H.F. Lee, et al.
Oral Presentation
Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations
Udagawa H, Hayashi H, Yamaguchi M, et al.